Health Enhancement Products, Inc. Study at the University of Missouri Indicates Positive Results for Canine Joint Health
February 03 2014 - 2:20PM
Marketwired
Health Enhancement Products, Inc. Study at the University of
Missouri Indicates Positive Results for Canine Joint Health
KEEGO HARBOR, MI--(Marketwired - Feb 3, 2014) - Health
Enhancement Products, Inc. (OTCQB: HEPI), which investigates and
licenses algae-derived, high-value bioactive molecules that benefit
human and animal health, announces preliminary research results for
efficacy in addressing canine joint health. The research was
conducted at the University of Missouri by Keiichi Kuroki, DVM,
PhD, DAVCP, Associate Director of the Comparative Orthopaedic
Laboratory and Associate Professor at the College of Veterinary
Medicine.
Dr. Kuroki is a member of a group of researchers at the
Comparative Orthopaedic Laboratory, University of Missouri, led by
professor James Cook, DVM, PhD, credited with developing an in
vitro co-culture model of canine osteoarthritis nearly a
decade ago. This well-regarded and proven model mimics the
histological, biochemical, and molecular features of osteoarthritis
in a laboratory setting.
Osteoarthritis, characterized by the progressive degradation of
joint cartilage, affects roughly one out of every five dogs,
causing stiffness, inflammation, and joint pain, thus hindering
quality of life. The initial results of the University of Missouri
study indicate that naturally-produced HEPI compounds help prevent
the loss of glycosaminoglycan, one of the major structural
components of cartilage and a good indicator of cartilage
health.
"This model, emblematically 'osteoarthritis in a test tube,' is
ideal for examining the effectiveness of potential treatment
options, including dietary supplements, to support joint health and
protect cartilage throughout an animal," said Amy Steffek, PhD,
HEPI Director of Research & Development. HEPI looks forward to
continuing their research with Dr. Kuroki and the Comparative
Orthopaedic Laboratory, University of Missouri to provide a natural
alternative that may help improve joint health in dogs and promote
a more active lifestyle.
About Health Enhancement Products,
Inc. Health Enhancement Products, Inc. is a health and
wellness company engaged in the development of algae-derived,
natural products for use as dietary supplements and food
ingredients. The company has developed a portfolio of natural,
bioactive compounds wholly owned by Health Enhancement Products and
protected by patents, patents pending, and trade secrets, which are
licensed to manufacturers. These natural products are extracted
from living algae grown in purified water.
About the University of Missouri
Comparative Orthopaedic Laboratory The mission of the
Comparative Orthopaedic Laboratory at the University of Missouri is
to design and conduct the highest quality hypothesis-driven
research focused on orthopaedic disorders of diarthrodial joints;
to implement a comparative approach to investigation of joint
disease in order to most efficiently and comprehensively address
identified problems; and to apply basic science research to the
clinical situation in order to span the gap that often limits the
usefulness of scientific discoveries. The laboratory is made
possible through collaboration among the University of Missouri
College of Veterinary Medicine, Missouri Orthopaedic Institute, and
the MU School of Medicine.
Safe Harbor Statement Except
for any historical information, the matters discussed in this press
release contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These forward-looking statements
involve risks and uncertainties. A number of factors could cause
actual results to differ from those indicated in the
forward-looking statements, including the timing of completion of a
trial, actual future clinical trial results being different than
the results the company has obtained to date, and the company's
ability to secure funding. Such statements are subject to a number
of assumptions, risks and uncertainties. Readers are cautioned that
such statements are not guarantees of future performance and those
actual results or developments may differ materially from those set
forth in the forward-looking statements. The company undertakes no
obligation to publicly update or revise forward-looking statements,
whether as a result of new information or otherwise.
Zivo Bioscience (QB) (USOTC:ZIVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zivo Bioscience (QB) (USOTC:ZIVO)
Historical Stock Chart
From Sep 2023 to Sep 2024